Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 2, 2004 - Issue 6
Submit an article Journal homepage
12
Views
4
CrossRef citations to date
0
Altmetric
Review

Is it time for medical therapy for aortic valve disease?

Nalini M Rajamannan Northwestern University Feinberg School of Medicine, Feinberg Cardiovascular Research Institute, 303 E Chicago Avenue, Tarry 12–703, Chicago, IL 60611, USA. [email protected]
Pages 845-854 | Published online: 10 Jan 2014

References

  • Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. I Am. Coll. Cardiol 21(5), 1220–1225 (1993).
  • Bonow RO, Cerebella B, de Leon AC Jr et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98(18), 1949–1984 (1998).
  • •Current American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cardiac evaluation for patients with valvular heart disease. Contains a very thorough review of the entire literature in the English language on the management of aortic valve disease.
  • Stokes W. The Diseases of the Heart and Aorta. Hodges & Smith, Dublin, Ireland, 211–212 (1645).
  • Chan KL. Is aortic stenosis a preventable disease? J Am. Coll Cardiol 42(4), 593–599 (2003).
  • Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. Arn. Coll. Cardiol 29(3), 630–634 (1997).
  • •The Cardiovascular Health Study was the first epidemiologic study to demonstrate the independent risk factors for calcific aortic stenosis.
  • Sprecher DL, Schaefer EJ, Kent KM et al Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients. Am. Cardiol 54,20–30 (1984).
  • Rajamannan NM, Edwards WD, Spelsberg TC. Brief report: histopathologic confirmation of hypercholesterolemic induced valvular heart disease. N Engl. J Med. 349(7), 717–718 (2003).
  • Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl. J Med. 341(3), 142–147 (1999).
  • Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J. Am. Col. Cardiol 13545–13550 (1989).
  • •Important echo study defining the echo parameters important in the development of severe aortic stenosis.
  • Cosmi JE, Kart S, Tunick PA et al. The risk of the development of aortic stenosis in patients with 'benign' aortic valve thickening. Arch. Intern. Med. 162, 2345–2347 (2002).
  • Agmon Y, Khandheria BK, Meissner I et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J. Arn. Coll. Cardiol 38, 827–834 (2002).
  • Galante A, Pietroiusti A, Vellini M et al C-reactive protein is increased in patients with degenerative aortic valvular stenosis. Arn. Coll. Cardiol 34,1078–1081 (2002).
  • Rosenhek R, Binder T, Porenta G et al. Predictors of outcome in severe asymptomatic aortic stenosis. N Engl. J Med. 343,611–617 (2001).
  • Oh JK, Taliercio CP, Holmes DR Jr et al. Prediction of the severity of aortic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. J. Am. Coll. Cardiol 11(6), 1227–1134 (1988).
  • Ross J Jr, Braunwald E. Aortic stenosis. Circulation 38 (Suppl. 1), 61–67 (1968).
  • •First study indicating the natural progression of patients with severe aortic stenosis.
  • O'Brien KD, Kuusisto J, Reichenbach DD et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92(8) 2163–2168 (1995).
  • Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation 103(11), 1522–1528 (2001).
  • Rajamannan NM, Subramaniam M, Rickard D. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107(17), 2181–2184 (2003).
  • O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arteriosder Thromb. Vast: Biol. 16(4), 523–532 (1996).
  • O'Brien KD, Shavelle DM, Caulfield MT et al Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106(17), 2224–2230 (2002).
  • Chockalingam A, Venkatesan S, Subramaniam T et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction — Pilot study of Enalapril in Aortic Stenosis (SCOPE-AS). Am. Heart J. 147(4), E19 (2004).
  • Khot UN, Novara GM, Popovic ZB et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N. Engl. J Med. 348,1756–1763 (2003).
  • Awan NA, DeMaria AN, Miller RR et al Beneficial effects of nitroprusside administration on left ventricular dysfunction and myocardial ischemia in severe aortic stenosis. Am. Heart J. 101,386–394 (1981).
  • Grace AA, Brooks NH, Schofield PM. Beneficial effects of angiotensin-converting enzyme inhibitors in severe symptomatic aortic stenosis. Eur Heart J. 12 (Suppl.), 129 (1991) (Abstract).
  • Sarphie TG. Surface responses of aortic valve endothelia from diet-induced, hypercholesterolemic rabbits. Atherosclerosis 45(2), 203–220 (1982).
  • Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J. Am. Coll. Cardiol 41 (7), 1211–1217 (2003).
  • Rajamannan NM, Sangiorgi G, Springett M et al Experimental hypercholesterolemia induces apoptosis in the aortic valve. j Heart Valve Dis. 10(3), 371–374 (2001).
  • Rajamannan NM, Gersh B, Bonow RO. Calcific aortic stenosis: from bench to the bedside — emerging clinical and cellular concepts. Heart 89 (7), 801–805 (2003).
  • Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. CUIT: Atherosclerosis Rep. 4(5), 363–372 (2002).
  • Rajamannan NM, Subramaniam M, Springeft M et al Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105(22), 2260–2265 (2002).
  • •First in vivo model of valve atherosclerosis demonstrating the effects of cholesterol and statins in the aortic valve.
  • Rajamannan NM, Subramaniam M, Stock SR et al Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolemic aortic valve. Heart (2004) (In press).
  • Pohle K, Maffert R, Ropers D et al Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104, 1927–1935 (2001).
  • Shavelle DM, Takasu J, Budoff MJ et al HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet359, 1125–1126 (2002).
  • Bellamy MF, Pellikka PA, Klarich KW et al Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community. J Arn. Coll. Cardiol 40, 1723–1730 (2002).
  • Aronow WS, Ahn C, Kronzon I et al Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older people. Am. j Cardiol 88, 693–695 (2001).
  • •First study to retrospectively evaluate the progression of aortic stenosis in patients who are taking statin agents.
  • Novara GM, Tiong 11, Pearce GL et al Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circuktion 104, 2205–2209 (2001).
  • Rossebo A, Pederson T, Skjaerpe T. Design of the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) study. Atherosclerosis 170(4), 253 (2003).
  • Herrick JB. A Short History of Cardiology CC Thomas, IL, USA, 231–232 (1942).
  • Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110 (10), 1180–1182 (2004).

Websites

  • Website of The Society of Thoracic Surgeons www.sts.org (Accessed October 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.